MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
NeoGenomics Accounts Payables 2011-2026 | NEO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables NeoGenomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.6 M | 20.3 M | 20.5 M | 17.9 M | 25 M | 19.6 M | 17.8 M | 10.4 M | 16.8 M | 12.5 M | 6.29 M | 4.18 M | 3.61 M | 2.53 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25 M | 2.53 M | 14.2 M |
Quarterly Accounts Payables NeoGenomics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.5 M | 16.2 M | 21.6 M | 16.5 M | 17.2 M | 18.3 M | 20.3 M | 16.8 M | 17.9 M | 22.7 M | 20.5 M | 13.7 M | 16.8 M | 20.5 M | 17.9 M | 28.5 M | 23.1 M | 18.9 M | 25 M | 25 M | 25 M | 25 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 6.29 M | 6.29 M | 6.29 M | 6.29 M | 4.18 M | 4.18 M | 4.18 M | 4.18 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 2.53 M | 2.53 M | 2.53 M | 2.53 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.5 M | 2.53 M | 14.3 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
165 K | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
 |
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 33.99 | 0.65 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
6.96 M | $ 1.38 | -6.12 % | $ 1.75 M | USA |
 |
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
6.9 M | $ 39.01 | -0.38 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
1.75 B | $ 218.94 | -0.24 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
89.6 M | $ 102.48 | 0.18 % | $ 19 B | USA |
 |
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
18.4 M | $ 26.01 | -0.88 % | $ 786 M | USA |
 |
Guardant Health
GH
|
38.6 M | $ 111.89 | 1.28 % | $ 13.7 B | USA |
 |
DexCom
DXCM
|
276 M | $ 73.26 | -1.0 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
12.9 M | $ 20.4 | -1.92 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
9.37 M | $ 109.94 | -1.94 % | $ 4.34 B | USA |
 |
DarioHealth Corp.
DRIO
|
1.13 M | $ 10.95 | 6.31 % | $ 311 M | Israel |
 |
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
34.6 M | $ 65.82 | -1.3 % | $ 4.55 B | USA |
 |
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
221 M | $ 145.95 | -2.5 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
322 M | $ 230.03 | -2.31 % | $ 41.7 B | USA |
 |
Charles River Laboratories International
CRL
|
140 M | $ 210.0 | -0.83 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
32.5 M | $ 583.39 | -1.63 % | $ 18.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
287 M | $ 184.82 | 1.37 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
2.19 M | $ 8.94 | -7.45 % | $ 1.16 B | USA |
 |
Personalis
PSNL
|
6.4 M | $ 9.4 | -5.72 % | $ 557 M | USA |
 |
Precipio
PRPO
|
622 K | $ 24.39 | 0.54 % | $ 31.7 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 269.39 | -0.16 % | $ 22.6 B | USA |
 |
Mettler-Toledo International
MTD
|
216 M | $ 1 384.16 | -0.62 % | $ 29.4 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
173 M | $ 179.07 | -3.67 % | $ 14.8 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
114 M | $ 674.78 | -0.29 % | $ 55.6 B | USA |
 |
Agilent Technologies
A
|
446 M | $ 132.75 | -0.37 % | $ 40.4 B | USA |
 |
Biomerica
BMRA
|
295 K | $ 2.39 | 0.21 % | $ 5.49 M | USA |